A Post-Transcriptional Regulatory Mechanism Restricts Expression of the Paraneoplastic Cerebellar Degeneration Antigen cdr2 to Immune Privileged Tissues

John P. Corradi,¹ Chingwen Yang,¹ Jennifer C. Darnell,¹ Josep Dalmau,² and Robert B. Darnell¹,²

¹Laboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, New York 10021, and ²Department of Neurology and the Cotzias Laboratory of Neuro-Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021

Paraneoplastic cerebellar degeneration (PCD) is believed to be an autoimmune disorder initiated by the ectopic expression of a neuron-specific protein in breast and ovarian tumors. PCD antisera was used previously to identify several cerebellar degeneration-related (cdr) genes encoding putative PCD antigens. We have found that the cdr2 gene, which encodes a cytoplasmic leucine zipper protein of unknown function, is expressed in PCD-associated tumors, whereas other cdr genes are not; thus, cdr2 encodes the PCD tumor antigen. To determine whether the expression pattern of cdr2 is consistent with its proposed role in PCD, we have isolated the mouse homolog and examined both the mRNA and protein distribution in adult tissues. We have found that cdr2 mRNA is expressed in almost all tissues, whereas the protein is expressed only in the brain and testes. Within the brain, both the cdr2 mRNA and immunoreactivity are confined primarily to neurons in the cerebellum and brainstem, the regions most affected in PCD. These results suggest first that the tissue-specific expression of cdr2 is regulated at a post-transcriptional level. Moreover, because the brain and testes are considered to be immune-privileged sites, the expression pattern of cdr2 is compatible with the autoimmune model of PCD pathogenesis.

Key words: paraneoplastic neurological disease; neuron-specific gene expression; translational regulation; immune privilege; cerebellar degeneration; leucine zipper protein

The paraneoplastic neurological disorders (PNDs) are a rare group of neuronal degenerations that develop as remote effects of systemic malignancies (for review, see Posner and Furneaux, 1990; Darnell, 1996). It is believed that the PNDs are immune-mediated, arising when systemic tumors express proteins (called onconeural antigens) that are normally entirely restricted in their expression to immune-privileged neurons. The serum and CSF of PND patients harbor high titers of anti-neuronal autoantibodies that are also reactive with their tumors (Anderson et al., 1988a; Furneaux et al., 1990; Luque et al., 1991). Characterization of the nature of the disorders and the onconeural antigens has been advanced by the use of PND antisera to clone cDNAs encoding the antigens. Studies of several onconeural antigens, including the breast tumor antigen Nova (Buckanovich et al., 1993, 1995) and the small cell lung cancer antigen Hu (Szabo et al., 1991; Dalmau et al., 1992), have demonstrated that the normal expression of their mRNA and protein is neuron-specific. Taken together with evidence that immunity to PND antigens correlates with effective anti-tumor immunity (Dalmau et al., 1990; Darnell and DeAngelis, 1993; Darnell, 1996), these observations suggest a model for PND in which the expression of onconeural antigens in tumor cells initiates an appropriate immune response that subsequently develops into autoimmune neurological disease.

Paraneoplastic cerebellar degeneration (PCD) is a PND that develops in patients with breast and ovarian tumors and is characterized by the presence of a specific autoantibody referred to as “anti-Yo” (Anderson et al., 1988b). Immunohistochemical studies with this antibody reveal that it reacts with both PCD-associated tumor cells (Furneaux et al., 1990) and discrete populations of neurons, reacting most strongly with cerebellar Purkinje cell cytoplasm (Cunningham et al., 1986). PCD antisera identify a major antigen reported as either 52 kDa (Tsukamoto et al., 1989; Sakai et al., 1991) or 62 kDa (Cunningham et al., 1986) and a minor antigen of 34 kDa when used in Western blot analysis of Purkinje cell extracts; the larger molecular weight antigen is readily detectable in PCD tumor extracts (Furneaux et al., 1990).

Using PCD antisera, cDNAs encoding three cerebellar degeneration related antigens (cdr1–3) have been identified. cdr1 encodes the 34 kDa protein, the predicted amino acid sequence of which reveals an unusual structure composed of nearly identical hexapeptide repeats making up 91% of the protein (Drochio et al., 1987). cdr2 was cloned independently from both HeLa cell and human cerebellar cDNA libraries (Fathallah-Shaykh et al., 1991; Sakai et al., 1991). This cDNA encodes a protein with a coiled coil/leucine zipper domain present near the N-terminus. A third cDNA (cdr3) cloned from an HeLa expression library (Fathallah-Shaykh et al., unpublished observations), GenBank accession L02867, shares significant homology (~45% predicted amino acid identity) with cdr2, but has not been investigated further.

It has been suggested that cdr2 may be widely expressed in normal tissues, which is problematic for its proposed role in the pathogenesis of PCD. Widespread expression of cdr2 would also...
be inconsistent with the clinical features of PCD, which are restricted to evidence of anti-tumor immunity and neuronal (primarily cerebellar) dysfunction (Peterson et al., 1992). Early studies using PCD antisera found immunoreactivity with cerebellar Purkinje cells when the antibody was used at limiting dilutions (Jaeckle et al., 1985). Subsequent reports have found Purkinje cell immunoreactivity at limiting antibody dilutions, but more widespread reactivity both within and outside the nervous system using high concentrations of antibody (Altermatt et al., 1991; Tomimoto et al., 1993). Furthermore, Sakai et al. (1991) detected the cdr2 mRNA in cerebellum, brainstem, and intestine by reverse transcription PCR (RT-PCR); additional samples were negative but were not controlled for integrity of the RNA.

The present study was undertaken to clarify the expression pattern of the PCD antigen. We have examined three clinical tumors for the expression of cdr genes and found that the cdr2 gene encodes the PCD tumor antigen. We then defined the tissue distribution of the cdr2 mRNA and immunoreactive protein in the adult mouse and have found that expression of the PCD antigen is restricted to the brain and tests, tissues that are recognized as sites of immunological privilege. These results demonstrate that the expression pattern of the PCD antigen is consistent with the proposed autoimmune model of PCD. Interestingly, the cdr2 mRNA displays a wider distribution than the protein, indicating that expression of the cdr2 antigen is regulated at a posttranscriptional level.

MATERIALS AND METHODS

Tumor RNA extraction and RT-PCR. Frozen samples of ovarian tumors removed from patients with Yo-positive PCD were obtained from the Memorial Sloan Kettering Cancer Center. Fragments (100 mg) were used for purification of either total or poly(A\(^+\)) RNA. Total RNA was prepared by the method of Chomcynski and Sacchi (1987), and the samples were subsequently treated with RQ1 RNase-free DNase (Promega, Madison, WI) before RT-PCR analysis. For the purification of poly(A\(^+\)) RNA, the section was homogenized by sonication in 400 \(\mu\)l wash buffer (4 M guanidinium thiocyanate, 0.1 M Tris-HCl, pH 8.0, 1% dithiothreitol, 0.5% lauryl sarcosinate), and 800 \(\mu\)l of binding buffer (1 M Tris-HCl, pH 8.0, 0.4 M LiCl, 20 mM EDTA) was added and the lysate clarified by centrifugation at 18,000 \(\times\) g for 5 min. Magnetic Dynabeads Oligo (dT)\(_{25}\) (Dynal, Great Neck, NY) were prepared by washing 300 \(\mu\)l of beads once with 200 \(\mu\)l binding buffer. The lysate supernatant was added to the Dynabeads, mixed, and incubated at room temperature for 3–5 min. A magnet was used to immobilize the beads, the supernatant was removed, and the beads were washed three times with 0.5 ml wash buffer (10 mM Tris-HCl, pH 8.0, 0.15 mM LiCl, 1 mM EDTA). Poly(A\(^+\)) RNA was then eluted in 20 \(\mu\)l 2 M EDTA, pH 8.0, at 65°C for 2 min.

For RT-PCR reactions, 2 \(\mu\)l tumor poly(A\(^+\)) RNA, 1–2 \(\mu\)g total tumor RNA, or 20 ng poly(A\(^+\)) RNA from normal tissues (CLONTECH Laboratories, Palo Alto, CA) was denatured at 70°C for 10 min and placed on ice. The RNA was reverse-transcribed using random hexanucleotide primers (Boehringer Mannheim, Indianapolis, IN) and Superscript reverse transcriptase (Life Technologies, Gaithersburg, MD) at 42°C for 50 min and the reaction stopped by incubation at 95°C for 5 min. One-tenth of the first strand cDNA sample was used as template for a PCR reaction using AmpliTaq polymerase (Perkin-Elmer, Norwalk, CT) and the following forward and reverse oligonucleotide primers corresponding to cdr2: 5'-TGAATGAGTTGGAGACGTGTGG-3' and 5'-GAGATGCGCCTTC-GTTTCCACAG-3' and cdr3: 5'-CATGAGGCTGGTCAGGCTTGGG-3' and 5'-AGCTCTGTGAG CAGGGGAAA-3'. The product was amplified for 35 cycles (94°C for 30 sec, 55°C for 30 sec, 72°C for 1 min). PCR products were labeled by addition of trace amounts of \([\alpha^{32}P]dCTP\) (Amersham Life Science, Arlington Heights, IL) to the reaction mixtures and loaded on a 10% non-denaturing acrylamide gel and visualized by autoradiography.

Two-dimensional (2-D) gel electrophoresis. Cerebellum and tests from Sm/Ckc mice were homogenized in 2-D lysis buffer [9.5 mM urea, 5% NP-40, 5% β-mercaptoethanol, 2% BioIyte ampholytes (BioRad Labs, Hercules, CA) consisting of 75% 3-5 range and 25% 3-10 range BioIyes], and protein concentrations were determined using the Bio-Rad Protein Assay (BioRad, Hercules, CA). Oligonucleotides were labeled with \(32P\)-labeled probes (Sambrook et al., 1989). The mouse brain library (1.2 \(\times\) 10\(^8\) pfu) was screened at low stringency with a probe corresponding to bp 1–872 of the human cdr2 cDNA (Fathallah-Shaykh et al., 1991). This screen resulted in the isolation of a single 2.4 kb clone. The mouse spleen library (\(6 \times 10^8\) pfu) was screened with a cDNA probe corresponding to bp 153–720 of the mouse brain cdr2 cDNA (see Fig. 2). This screen resulted in the isolation of three overlapping clones, one comprising the full coding regions and untranslated regions (UTR). The cDNA clones were sequenced by the dideoxy method of Sanger et al. (1977) using Sequenase 2.0 (United States Biochemical, Cleveland, OH), and sequence data were analyzed using the MacVector software package (International Biotechnologies, New Haven, CT).

Northern blot analysis. Adult ICR (Charles River) mouse organs were dissected, and total RNA was prepared using the TRIZOL Reagent (Life Technologies) and the protocol recommended by the manufacturer. Total RNA (30 \(\mu\)g) was resolved on an agarose/50% glyoxal gel (Sambrook et al., 1989) and transferred to Biodyne B nylon membrane (FALL, Glen Cove, NY). The RNA was UV cross-linked to the membrane, and the blot was prehybridized in 6× SSC, 0.5% SDS, 5× Denhardt’s solution, 0.05% sodium pyrophosphate, 100 \(\mu\)g/ml denatured herring sperm DNA for 30 min at room temperature. cDNAs corresponding to a 580 bp fragment of the mouse cdr2 3'-UTR and the full-length GAPDH coding region were labeled with \([\alpha^{32}P]dCTP\) using the Prime-It Kit (Stratagene). The RNA blot was hybridized with 1 \(\times\) 10\(^6\) cpm/ml labeled probe in 6× SSC, 0.5% SDS, 0.2% sodium dodecyl sulfate (SDS) for 30 hr at 55°C. The blot was washed twice in 2× SSC, 0.1% SDS, 0.1% sodium pyrophosphate at 65°C, and twice in 0.1× SSC, 0.1% SDS, 0.1% sodium pyrophosphate at room temperature, and hybridization was visualized by autoradiography.

Antibody affinity purification and Western blot analysis. The region coding for amino acids 16–192 of human cdr2 was fused in frame to glutathione-S-transferase (GST) in the GSTag vector (the gift of David Ron, New York University). Bacteria transformed with the GSTag-cd2 plasmid were grown to an \(OD_{600}\) of 0.5 and 1 mM isopropyl thigalacto-side added for an additional 3 hr. Cells were harvested and resuspended in ice-cold PBS and lysed by sonication, and the lysate cleared by centrifugation. The cleared lysate was incubated with glutathione Sepha-dex A-50 (Pharmacia Biotech) (1 ml) and washed with PBS/0.5% Biolyte ampholytes, and GST-fusion protein eluted with 10 mM reduced glutathione. Purity and immunoreactivity of the GST-cd2 fusion protein were verified by SDS-PAGE, Coo-massie blue staining, and Western blot analysis.

For affinity purification of PCD antisera, Immobilon membrane (Millipore, Bedford, MA) was wetted with methanol and rinsed well with ddH\(_2\)O. GST-cd2 fusion protein (20–30 \(\mu\)g) was spotted on a 0.5 × 3 cm strip of membrane and blocked for 60 min in 25 mM Tris-HCl, pH 8.0, 20 mM Na\(_2\)SO\(_4\), 150 mM NaCl, 5% nonfat dry milk. The strip was washed with PBS/0.02% sodium azide and incubated with 1 ml of PCD antiserum for 2 hr at 4°C. The strip was then washed four times with 25 mM Tris-HCl, pH 8.0, 20 mM Na\(_2\)SO\(_4\), 150 mM NaCl, 2% SDS, and antibody was eluted with 1 ml 0.2 M glycine, pH 3.0. The elution was repeated with the positive control without PCD antibody or to a final pH of 7.5–8.0. Ultrafiltration in a Centricon-10 unit (Amicon, Beverly, MA) was used to remove the glycine from the affinity-purified antibody.

For Western blot analysis, the indicated tissues were dissected from adult ICR mice and homogenized in PBS, 2× SDS sample buffer added, and the samples boiled. Frozen sections of PCD ovarian tumors were pulverized with a mortar and pestle under liquid nitrogen and homogenized in lysis buffer (10 mM Tris-HCl, pH 7.4, 50 mM Na\(_2\)PO\(_4\), 50 mM potassium fluoride, 1% NP-40, 5 mM EDTA). Total protein (45 \(\mu\)g) from each tissue extract was resolved by 10% SDS-PAGE and transferred to nitrocellulose membrane. Blots were incubated with affinity-purified PCD antibody diluted to 1:50 or native PCD antiserum diluted to 1:400, washed, and incubated with anti-human IgG conjugated to horseradish peroxidase (Amersham) at 1:5,000 dilution. Reactive proteins were detected using the ECL kit (Amersham) according to the manufacturer’s instructions and stripped of antibody according to the ECL protocol.
with 40 μg of total protein per lane, and the samples were covered with sample overlay buffer (7% urea, 2.5% am- 
photolytes, 5% β-mercaptoethanol). The gels were run using 0.01 M H₃PO₄ and 0.02 M NaOH buffers, as described by O’Farrell (1975) at 4 W constant power. Voltage was limited to 700 V, and gels were run for 1800 V/hr. Lanes containing the samples were cut from the gel, equilibrated with 1× SDS sample buffer for 5 min, and loaded horizontally onto a 1 mm 9% SDS-PAGE gel with a 3% stacking gel. A single well was loaded with 40 μg protein extract in SDS sample buffer for one-dimensional analysis. Gels were transferred to nitrocellulose and probed with PCD antisera.

In situ hybridization. The protocol used was essentially the same as that described by Newman et al. (1995). Adult ICR mouse tissues were embedded and frozen in O.C.T. compound (Miles, Elkhart, IN). Sections (10 μm) were cut using a cryostat and applied to Probe-On Plus slides (Fisher Scientific, Pittsburgh, PA). A plasmid containing the same region of the 3’-UTR of the mouse cdr2 gene as that used for the Northern blot was linearized and both sense and antisense riboprobes transcribed using T7 RNA polymerase (Stratagene) and [33P]UTP (Dupont NEN, Boston, MA). Probe was purified on a Sepharose G50 column and hybridized to tissue sections at 50°C for 36–48 hr. Immunohistochemistry. For the human tissues, IgG from PCD and normal human sera was isolated and biotinylated, as described previously (Furneaux et al., 1990). Paraffin-embedded sections of ovarian tumor and cerebellum from PCD patients were reacted with the biotinylated antibo- 
dies, as described by Verschuren et al. (1996).

For the mouse tissues, whole organs were dissected from adult ICR mice and tissues were embedded in O.C.T. compound. Sections (10 μm) were fixed in methanol/0.3%H₂O₂ at room temperature for 30–60 min to quench endogenous peroxidase activity, washed in PBS, and blocked with PBS/2% normal goat serum (NGS) at room temperature for 1 hr. Sections were incubated with primary antibody diluted in PBS/2% NGS at 4°C overnight, washed in PBS, and incubated with biotinylated anti-human IgG (Vector Laboratories, Burlingame, CA) diluted 1:5000 in PBS/2% NGS at room temperature for 1–2 hr. The signal was enhanced by addition of an avidin–biotin complex (Vectastain Elite Kit, Vector Laboratories) and visualized with diaminobenzidine in the presence of H₂O₂.

RESULTS
Detection of cdr2 message in PCD-associated ovarian tumors

Previous studies demonstrated that PCD antisera recognized a protein of ~62 kDa in all PCD tumor samples examined but detected the 34 kDa species (cdr1) in only one (Furneaux et al., 1990), suggesting that cdr2 might encode the PCD tumor antigen. However, the antigenic epitope in cdr2 localizes to the leucine zipper domain of the protein (Sakai et al., 1993), which is nearly identical in sequence to the leucine zipper of cdr3, and both cDNAs were cloned using PCD antisera. To address which of these two genes encodes the in vivo PCD tumor antigen, we assayed PCD tumors for the presence of cdr gene transcripts by RT-PCR. Single-strand cDNA was synthesized from poly(A⁺) RNA purified from tumor tissue or human cerebellar poly(A⁺) RNA was used as templates for the RT. Gene-specific primers corresponding to the coding region of either cdr2 or cdr3 were used for PCR amplification of the first strand cDNA. Reactions were performed both in the presence and absence of RT to control for DNA contamination. A β-actin primer pair was also used as a control for RNA integrity (data not shown). Although the transcripts of the expected size for both cdr2 and cdr3 were detectable in human cerebellum, only the cdr2 transcript was detected in the PCD tumors.

To confirm that the cdr2-positive PCD tumors we assayed came from typical PCD patients, we examined tumor tissue for immu- 
noreactivity with PCD antisera. Figure 2 demonstrates that tumor tissue from one patient (tumor 2) was immunoreactive with PCD antisera (Fig. 2B) but not control antisera (Fig. 2A); similar results were found with tumors 1 and 2 (data not shown). In addition, we assayed tissue from tumor 3 for PCD reactivity by Western blot analysis. Figure 2C demonstrates that PCD antisera recognized a protein that comigrates with the PCD antigen rec-
ognized in human Purkinje extracts. Finally, we examined cere- 
bellar tissue obtained from the autopsy of patient 3. Immunohis- 
tochemical analysis of cerebellar tissue using PCD antisera revealed the complete absence of immunoreactivity and Purkinje neurons in PCD cerebellum (Fig. 3A) but showed a characteristic staining pattern in Purkinje neurons of control cerebellum (Fig. 3B). We conclude from the RT-PCR and protein studies that the PCD tumor antigen is the cdr2 gene product.

To facilitate the study of cdr2 expression, we used a human cdr2 cDNA clone (Fathallah-Shaykh et al., 1991) to isolate a 2.4 kb cDNA encoding cdr2 from an adult mouse brain library (Fig. 4). Because the initiating methionine of the human cDNA has not been defined (Fathallah-Shaykh et al., 1991; Sakai et al., 1991), we compared the degree of nucleic acid homology between the murine and human cdr2 sequences. The sequence homology decreases dramatically immediately upstream of a methionine codon at position 154, and there is an in-frame stop codon at position 88, indicating that this ATG is the initiation codon. The full-length murine cdr2 open reading frame encodes a protein of predicted molecular weight 52 kDa, and its amino acid sequence is 87% identical to its human homolog (Fig. 4). Within the region of the antigenic epitope (the leucine zipper domain), the mouse and human proteins are identical.
cdr2 mRNA is expressed widely in adult mouse tissues, but the protein is restricted to the brain and testis

To determine whether cdr2 gene expression was limited to the nervous system, we performed Northern blot analysis using a cdr2-specific cDNA probe. A single cdr2 transcript of 2.8 kb was detected in eight of nine tissues examined; it was most abundant in testis and spleen and was not detectable in liver (Fig. 5A). This result was confirmed by hybridization with a probe from a different region of the cdr2 gene (data not shown) and by RT-PCR analysis of mouse cerebellum, spleen, heart, and testis RNA (Fig. 5B and data not shown). The cdr2 primer pair used for PCR amplification flanks the region encoding the PCD epitope, suggesting that this region of the cdr2 transcript is the same in each tissue.

To investigate the expression pattern of the PCD antigen, Western blot analysis using affinity-purified PCD antisera was performed on the same battery of adult mouse tissues used for Northern blot analysis. Interestingly, a single band of \( M_r = 56 \) kDa was detected in cerebellum and testis but not in other tissues (Fig. 6A). On a longer exposure, a faint band was also detected in the cerebral cortex (data not shown). The blot was stripped of antibody and reprobed with a monoclonal antibody to \( \beta \)-tubulin (Fig. 6A), demonstrating that equivalent amounts of protein were loaded in each lane. To confirm the identity of the immunoreactive species in brain and testis, we performed 2-D gel electrophoretic analysis. Figure 6B shows that the protein recognized by PCD antisera in cerebellum (top panel) and testis (bottom panel) exactly comigrate by both their molecular weights and isoelectric points (pI). The protein(s) runs
as a broad band with a pI of 6.1–6.4, consistent with previous 2-D gel analysis of human Purkinje cell lysate (Cunningham et al., 1986). This migration pattern in the dimension of isoelectric focusing could be attributable to post-translational or chemical modifications and may also explain the difference between the observed pI and the predicted pI of 4.76.

There are several potential explanations for the discrepancy between the tissue distribution of the cdr2 message and the protein detected by the PCD antisera. In tissues other than brain and testis, the PCD antigen may not be recognized by the Yo antibody as a result of alternative processing of the primary transcript, differential post-translational modification of the protein, or other factors. Additionally, the antibody may recognize epitopes that are not preserved in the protein product.

Figure 4. Nucleotide and predicted amino acid sequence of the adult mouse brain cdr2 cDNA. Amino acids are numbered on the left and the nucleotides on the right. The in-frame stop codon upstream of the presumptive initiating methionine and a polyadenylation signal are underlined. The translational stop codon is indicated with an asterisk. The 455 amino acid protein of predicted M, = 52 kDa is 87% identical to the human sequence. The amino acids that are not conserved are underlined.

The nucleotide and predicted amino acid sequence of the adult mouse brain cdr2 cDNA. Amino acids are numbered on the left and the nucleotides on the right. The in-frame stop codon upstream of the presumptive initiating methionine and a polyadenylation signal are underlined. The translational stop codon is indicated with an asterisk. The 455 amino acid protein of predicted M, = 52 kDa is 87% identical to the human sequence. The amino acids that are not conserved are underlined.
**cdr2 expression is also regulated at the level of transcription**

To extend our cdr2 expression data, the tissue distribution of cdr2 mRNA and protein was compared by in situ hybridization and immunohistochemistry. A specific in situ hybridization probe was generated from the mouse cdr2 3'-UTR, and the expression in mouse tissues was compared with the pattern of immunoreactivity seen with affinity-purified or native PCD serum. Both sagittal and coronal sections of adult mouse brain showed a pattern of cdr2 mRNA expression that corresponded precisely to the pattern of immunoreactivity. Abundant cdr2 mRNA and PCD antigen was detected specifically in the cerebellar Purkinje cells, in neurons of the deep cerebellar nuclei, and in brainstem (Fig. 7A, B). cdr2 mRNA and protein were absent from hippocampus, basal ganglia, and neocortex, with the exception of scattered immunoreactive cortical neurons (data not shown).

Outside the nervous system, there was no correlation between cdr2 in situ hybridization and immunohistochemistry except in testis. In sections of adult spleen, the cdr2 mRNA was readily detected, where it was found to be restricted to the splenic cortex (an area rich in lymphocytes) but absent from the red pulp (Fig. 7C). In contrast, there was no detectable cdr2 immunoreactivity in either the splenic cortex or the pulp (Fig. 7D). Similarly, no immunoreactivity could be detected in any other non-neuronal tissue examined except testis. Immunohistochemical staining of tissues revealed that cdr2 cytoplasmic reactivity was restricted to the outermost cell layer of the seminiferous tubules (Fig. 7F). By their relative position in the tubules and by morphological criteria, these cells appear to be spermatogonia, the least-differentiated type in the germ cell lineage. In situ hybridization of testis revealed that cdr2 mRNA is abundantly expressed in spermatogonia and could be detected to a lesser degree in early differentiating spermatocytes (Fig. 7E). Taken together, these data demonstrate an uncoupling of cdr2 mRNA and protein expression, suggesting that a post-transcriptional mechanism restricts cdr2 protein expression to spermatogonia and a subset of neurons.

**DISCUSSION**

**The onconeural antigen cdr2**

Three genes encoding putative PCD antigens have been identified by expression library screening with PCD antisera (Dropcho et al., 1987; Fathallah-Shaykh et al., 1991; Sakai et al., 1991), but which of these encode proteins that might be relevant to PCD in vivo has been uncertain. Western blot analysis of PCD tumor tissue probed with PCD antisera previously identified immunoreactive species that might correspond in size to either the cdr2 or cdr3 gene products (Furneaux et al., 1990). Moreover, the cdr2 and cdr3 genes encode proteins that share a common epitope (the leucine zipper domain). We have performed RT-PCR analysis of three PCD-associated ovarian tumors and found that in each of these tumors, the only PCD-related gene to be expressed is cdr2, and we conclude that the cdr2 protein is the PCD tumor antigen.

Based on RNA analysis and immunohistochemical studies (Sakai et al., 1991; Tomimoto et al., 1993), it had been thought previously that the PCD antigen cdr2 might be expressed outside the nervous system, generating uncertainty regarding its role as an onconeural antigen. We have demonstrated that the expression of the PCD antigen is normally restricted to neurons and testis, sites exhibiting the characteristics of immune privilege. Two-dimensional gel analysis confirms that the immunoreactive species evident on Western blot analysis is the same protein in both

---

**Figure 5.** Expression of the cdr2 mRNA in adult mouse tissues. A, A Northern blot of total RNA prepared from the indicated tissues was hybridized with a 32P-labeled cDNA probe made from the 3'-UTR of mouse cdr2 (top panel). The bottom panel shows hybridization of a GAPDH probe to the same blot as a control for loading of RNA. The mouse tissues used in the analysis were cerebellum (Cb), cerebral cortex (Cx), heart (Ht), lung (Lu), liver (Li), kidney (Kd) spleen (Sp), ovary (Ov), and testis (Ts). The relative positions of 28S (5.1 kb) and 18S (2.0 kb) rRNA are shown. A single cdr2 transcript of 2.8 kb was detected in all tissues tested, with the exception of the liver. B, RT-PCR analysis of cdr2 expression in cerebellum versus spleen RNA was performed, as described in Figure 1, using primers flanking the PCD epitope or β-actin primers. The cdr2 transcript was also detected in heart and testis by this assay (data not shown).
tissues. This expression pattern is consistent with the proposed role of cdr2 as an onconeural antigen.

The expression of previously characterized onconeural antigens and some autoimmune antigens has been found to be very tightly restricted to neurons. The Nova and Hu onconeural antigens are RNA-binding proteins expressed exclusively in neurons both early in embryogenesis and in adults (Szabo et al., 1991; Dalmau et al., 1992; Buckanovich et al., 1993, 1995). Similarly, the autoimmune cerebellar degeneration antigen β-NAP is a neuron-specific vesicle coat protein (Newman et al., 1995), and the stiff-man syndrome antigens GAD (Solimena et al., 1988) and amphiphysin (De Camilli et al., 1993) are nerve terminal vesicle-associated proteins. Our findings are thus concordant with the strict regulation of onconeural antigen expression but indicate that their expression may extend to immune-privileged cells outside the nervous system.

The phenomenon of immune privilege, traditionally described as the prolonged survival of allogeneic or xenogeneic grafts, has been studied most extensively in the brain, eye, and testis (Streilein, 1993). Immune privilege in the nervous system has both a physical and a molecular component, defined by the blood–brain barrier and the lack of detectable MHC class I or II antigens, respectively (Bradbury, 1984; Pollack and Lund, 1990). There are also active mechanisms by which immune-privileged tissues evade immune surveillance. For example, cells in the anterior chamber of the eye and the testis express fas ligand as a means of inducing apoptosis of autoreactive immune cells (Bellgra u et al., 1995; for comments, see Griffith et al., 1995). Although these studies have examined the immune response to foreign antigens expressed within immune-privileged tissues, they imply that proteins normally restricted in their expression to such sites may be highly immunogenic when ectopically expressed.

In PND, it is believed that sequestration of onconeural antigens from immune surveillance in the brain results in lack of immune tolerance to these proteins when they are ectopically expressed in tumor cells. We have shown that cdr2 is the only cdr gene expressed in ovarian tumors from PCD patients, and this appears to be the inciting onconeural antigen. Ectopic expression of cdr2 is associated with a robust immune response to the antigen. The presence of a specific high-titer autoantibody and limited tumor growth in PCD patients provide clinical evidence for an active anti-tumor immune response (Anderson et al., 1988b; Peterson et al., 1992) and suggest that the cdr2 protein may act as a bona fide tumor antigen.

It remains uncertain how a systemic immune response to ectopically expressed cdr2 protein becomes competent to recognize the antigen within the brain. However, it does appear that the autoimmune response within the nervous system in PCD is likely to be directed against cdr2. Pathological examination of PCD brains reveals degeneration of the same neurons in which cdr2 is expressed, most prominently Purkinje neurons of the cerebellum (Fig. 3) (Peterson et al., 1992; Verschuuren et al., 1996). Taken together, these observations suggest that autoimmunity to cdr2 in PCD proceeds in two steps. First, a naive immune system is naturally competent to recognize cdr2 in PCD tumors. A second unidentified event, perhaps involving cytokines or a change in the nature of the cellular immune response, allows the immune privilege of the brain to be breached, culminating in autoimmune neurological disease.

**Regulation of the cdr2 antigen at a post-transcriptional level**

We have clarified the nature of PCD by definitively identifying cdr2 as the neuronal gene that is ectopically expressed in PCD tumors. Given the significance of such onconeural genes to tumor biology and neurobiology (for review, see Darnell, 1996), this observation focuses attention on studies of the regulation of cdr2 expression. We have defined the tissue-specific expression pattern of the cdr2 antigen and found that it is regulated at a post-transcriptional level. A single cdr2 transcript is detected in nearly all tissues, whereas the PCD antigen is expressed specifically in brain and testis. Sequence analysis of both brain and spleen cdr2 cDNAs reveals that these mRNAs are identical, indicating that there is a tissue-specific regulatory mechanism responsible for restricting expression of the cdr2 protein that operates after mRNA processing.

The discrepancy between the distribution of cdr2 message and protein suggests several possible underlying mechanisms. Perhaps the most likely is that translational control regulates the expression of cdr2. Such a mechanism might relate either to an induction of translation specifically in brain and testis or a repression of translation in other tissues. There are several examples of tissue- or cell type-specific regulation of translation, including the testis proenkephalin mRNA, S-adenosylmethionine decarboxylase and
the transcription factor BTEB (Hill and Morris, 1992; Rao and Howells, 1993; Imataka et al., 1994). Interestingly, the expression of BTEB closely resembles that of cdr2, in that the mRNA is detected in many tissues, whereas the protein is found only in brain and testis.

Most cases of translational regulation involve sequence elements in the 5’ or 3’-UTRs of the mRNA. These elements may form stable secondary structures that either directly impede the translation initiation complex or may act as binding sites for trans-acting regulatory factors (Melefors and Hentze, 1993). In addition to complex secondary structure, many tightly regulated genes contain multiple upstream AUG codons (uAUGs), often present in long 5’-UTRs, that serve to decrease translation efficiency (Kozak, 1989, 1991a,b; Geballe and Morris, 1994). Both

Figure 7. Analysis of cdr2 expression by *in situ* hybridization (A, C, E) and immunohistochemistry (B, D, F). Sections of adult mouse brain (A, B), spleen (C, D), and testis (E, F) were hybridized with a 32P-labeled cdr2 riboprobe or reacted with either affinity-purified or native PCD antisera. Dark-field photomicrographs reveal that the cdr2 mRNA is detected in cerebellar Purkinje neurons, many brainstem neurons (A), splenic cortical cells (C), and cells of the outermost layers of the seminiferous tubules in the testis (E). There was no clear pattern of expression in the cerebral cortex, and no hybridization was observed with cdr2 sense probes in any of the tissues examined (data not shown). Immunoreactivity with affinity-purified or native PCD antisera was detected in cerebellar Purkinje neurons, brainstem neurons (B, left and right panels, respectively), scattered neurons of the cerebral cortex (data not shown), and spermatogonia in the testis (F). Immunoreactivity was absent in spleen (D), which shows only background reactivity when compared with a normal human serum control (data not shown). pc, Purkinje cells; gcl, granule cell layer; ml, molecular layer; io, inferior olive; rp, red pulp; ctx, cortex; spg, spermatogonia; spc, spermatocytes.
S-adenosylmethionine decarboxylase and BTEB require the presence of such uAUGs in their 5' UTRs for inhibition of translation. The 5' UTR of human and mouse cdr2 cDNAs have ~80% G + C content in the 135 bp immediately upstream of the initiating methionine, predicting stable secondary structure. In addition, there are specific sequence elements within the cdr2 5' UTR that are conserved across species.

Several alternate explanations for the discrepancy between the expression of cdr2 mRNA and protein may be considered. The cdr2 protein could be translated constitutively but selectively unstable because of a tissue-specific degradation mechanism. Although there are examples of proteins targeted for degradation in response to specific signals, there is little precedence for such a mechanism regionally restricting protein expression. Moreover, our observation that the cdr2 protein is able to be expressed at high levels when transfected into non-neuronal cells (data not shown) suggests that the stability of the protein is not likely to be dependent on tissue-specific factors.

It is also possible that our results reflect tissue-specific differences in post-translational modifications affecting the PCD epitope, such that the protein is only immunoreactive in brain and testis. Notably, the cdr2 leucine zipper harbors several potential phosphorylation sites. However, we have found that bacterially expressed cdr2 fusion protein, full-length cdr2 translated in reticulocyte lysate, and cdr2 protein expressed in a transfected fibroblast cell line are all readily detected by PCD antisera (Corradi and Darnell, unpublished observations). Therefore, it is unlikely that a neuron-specific post-translational modification, or lack thereof, is a significant factor in recognition of the cdr2 epitope. A more direct approach to address this question would be to generate antibodies against other epitopes of the cdr2 protein to examine expression of the antigen.

REFERENCES


Sakai K, Ogawara T, Hirose G, Jaekcle KA, Greenlane JE (1993) Anal-